Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1999 Apr;80(4):348–352. doi: 10.1136/adc.80.4.348

Improvement of nebulised antibiotic delivery in cystic fibrosis

D Wilson 1, M Burniston 1, E Moya 1, A Parkin 1, S Smye 1, P Robinson 1, J Littlewood 1
PMCID: PMC1717907  PMID: 10086942

Abstract

AIM—To investigate deposition patterns and to assess the delivery rate of two nebuliser systems in children with cystic fibrosis (CF).
METHODS—Thirty three children with CF on regular treatment with nebulised antibiotics had radioisotope scans performed using technetium-99m labelled aerosol antibiotic generated by a Ventstream nebuliser (median mass diameter (MMD), 3.3 µm; delivery rate, 0.075 ml/min) under conditions similar to their routine home practice. The inhomogeneity of the images was scored on a 1-10 rating scale (a low score indicating even distribution of the antibiotic), and stomach deposition was measured as a percentage of overall deposition. Twenty patients had a repeat scan using an Optimist nebuliser (MMD, 1.8 µm; delivery rate, 0.02 ml/min).
RESULTS—The mean inhomogeneity scores were 5.4 in the Ventstream group and 3.5 in the Optimist group. Mean stomach deposition was 17.3% in the 33 patients using the Ventstream nebuliser. There was an inverse relation between height and stomach deposition (r = 0.69). In the 20 patients who had both nebulisers, the mean percentages of stomach deposition for the Ventstream and Optimist nebulisers were 11.8% and 1.6%, respectively. The Ventstream nebuliser delivered antibiotic at an average 2.8 times faster rate than the Optimist nebuliser.
IMPLICATIONS—A smaller particle size results in a more homogenous distribution of the antibiotic in the lungs with decreased stomach deposition. This should not be seen as a recommendation to use the Optimist nebuliser because more antibiotic was delivered to most parts of the lung with the Ventstream because of its increased delivery rate.



Full Text

The Full Text of this article is available as a PDF (108.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chua H. L., Collis G. G., Newbury A. M., Chan K., Bower G. D., Sly P. D., Le Souef P. N. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J. 1994 Dec;7(12):2185–2191. doi: 10.1183/09031936.94.07122185. [DOI] [PubMed] [Google Scholar]
  2. Everard M. L., Hardy J. G., Milner A. D. Comparison of nebulised aerosol deposition in the lungs of healthy adults following oral and nasal inhalation. Thorax. 1993 Oct;48(10):1045–1046. doi: 10.1136/thx.48.10.1045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Frederiksen B., Thorsteinsson S. L., Koch C., Høiby N. Forbedret prognose for patienter med cystisk fibrose. Et resultat of aggressiv centerbehandling. Ugeskr Laeger. 1997 Sep 22;159(39):5790–5794. [PubMed] [Google Scholar]
  4. Hodson M. E., Penketh A. R., Batten J. C. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet. 1981 Nov 21;2(8256):1137–1139. doi: 10.1016/s0140-6736(81)90588-2. [DOI] [PubMed] [Google Scholar]
  5. Laube B. L., Chang D. Y., Blask A. N., Rosenstein B. J. Radioaerosol assessment of lung improvement in cystic fibrosis patients treated for acute pulmonary exacerbations. Chest. 1992 May;101(5):1302–1308. doi: 10.1378/chest.101.5.1302. [DOI] [PubMed] [Google Scholar]
  6. Laube B. L., Links J. M., LaFrance N. D., Wagner H. N., Jr, Rosenstein B. J. Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients. Chest. 1989 Apr;95(4):822–830. doi: 10.1378/chest.95.4.822. [DOI] [PubMed] [Google Scholar]
  7. Laube B. L., Links J. M., Wagner H. N., Jr, Norman P. S., Koller D. W., LaFrance N. D., Adams G. K., 3rd Simplified assessment of fine aerosol distribution in human airways. J Nucl Med. 1988 Jun;29(6):1057–1065. [PubMed] [Google Scholar]
  8. Littlewood J. M., Miller M. G., Ghoneim A. T., Ramsden C. H. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet. 1985 Apr 13;1(8433):865–865. doi: 10.1016/s0140-6736(85)92222-6. [DOI] [PubMed] [Google Scholar]
  9. Littlewood J. M., Smye S. W., Cunliffe H. Aerosol antibiotic treatment in cystic fibrosis. Arch Dis Child. 1993 Jun;68(6):788–792. doi: 10.1136/adc.68.6.788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mukhopadhyay S., Staddon G. E., Eastman C., Palmer M., Davies E. R., Carswell F. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med. 1994 Mar;88(3):203–211. doi: 10.1016/s0954-6111(05)80348-8. [DOI] [PubMed] [Google Scholar]
  11. Newman S. P., Woodman G., Clarke S. W. Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern. Thorax. 1988 Apr;43(4):318–322. doi: 10.1136/thx.43.4.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. O'Doherty M. J., Thomas S. H., Gibb D., Page C. J., Harrington C., Duggan C., Nunan T. O., Bateman N. T. Lung deposition of nebulised pentamidine in children. Thorax. 1993 Mar;48(3):220–226. doi: 10.1136/thx.48.3.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. O'Doherty M. J., Thomas S., Page C., Clark A. R., Mitchell D., Heduan E., Nunan T. O., Bateman N. T. Does 99Tcm human serum albumin alter the characteristics of nebulized pentamidine isethionate? Nucl Med Commun. 1989 Jul;10(7):523–529. doi: 10.1097/00006231-198907000-00013. [DOI] [PubMed] [Google Scholar]
  14. Ramsey B. W., Dorkin H. L., Eisenberg J. D., Gibson R. L., Harwood I. R., Kravitz R. M., Schidlow D. V., Wilmott R. W., Astley S. J., McBurnie M. A. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993 Jun 17;328(24):1740–1746. doi: 10.1056/NEJM199306173282403. [DOI] [PubMed] [Google Scholar]
  15. Thomas S. H., Batchelor S., O'Doherty M. J. Therapeutic aerosols in children. BMJ. 1993 Jul 24;307(6898):245–247. doi: 10.1136/bmj.307.6898.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Thomas S. H., O'Doherty M. J., Graham A., Page C. J., Blower P., Geddes D. M., Nunan T. O. Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers. Thorax. 1991 Oct;46(10):717–721. doi: 10.1136/thx.46.10.717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Touw D. J., Brimicombe R. W., Hodson M. E., Heijerman H. G., Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J. 1995 Sep;8(9):1594–1604. [PubMed] [Google Scholar]
  18. Valerius N. H., Koch C., Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991 Sep 21;338(8769):725–726. doi: 10.1016/0140-6736(91)91446-2. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES